Glibenclamide reduces blood glucose in all of the following EXCEPT:
(Ref: KDT 6/e p266) Sulfonylureas decrease blood glucose in diabetics as well as non-diabetics. It requires at least 30% of functional beta cells for their action. Insulin is the only treatment for type 1 doanetes.
Non diabetics
Type 1 diabetics
Type 2 diabetics
Obese diabetics
Other topics and Adverse effects